WO1994022467A1 - Analogs of peptide yy and uses thereof - Google Patents

Analogs of peptide yy and uses thereof Download PDF

Info

Publication number
WO1994022467A1
WO1994022467A1 PCT/US1994/003380 US9403380W WO9422467A1 WO 1994022467 A1 WO1994022467 A1 WO 1994022467A1 US 9403380 W US9403380 W US 9403380W WO 9422467 A1 WO9422467 A1 WO 9422467A1
Authority
WO
WIPO (PCT)
Prior art keywords
arg
leu
pyy
seq
compound
Prior art date
Application number
PCT/US1994/003380
Other languages
French (fr)
Inventor
Ambikaipakan Balasubramaniam
Original Assignee
University Of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Cincinnati filed Critical University Of Cincinnati
Priority to AU66214/94A priority Critical patent/AU685803B2/en
Priority to EP94913965A priority patent/EP0692971A4/en
Priority to JP6522278A priority patent/JPH08510205A/en
Priority to KR1019950704035A priority patent/KR960701653A/en
Priority to SK1218-95A priority patent/SK121895A3/en
Publication of WO1994022467A1 publication Critical patent/WO1994022467A1/en
Priority to FI954559A priority patent/FI954559A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to peptide derivatives which are useful as therapeutic agents in the treatment of gastroenterological disorders.
  • Peptide YY is a 36-residue peptide amide isolated originally from porcine intestine, and localized in the endocrine cells of the gastrointestinal tract and pancreas (Tatemoto et al. Proc. Natl . Acad. Sci . 79:2514, 1982) .
  • Peptide YY has N-terminal and C-terminal tyrosine amides; accordingly, these two tyrosines give PYY its name (Y represents the amino acid tyrosine in the peptide nomenclature).
  • PYY shares a number of central and peripheral regulatory roles with its
  • NPY homologous peptide neuropeptide Y
  • PYY has been implicated in a number of physiological activities including nutrient uptake (see, e.g., Bilcheik et al. Digestive Disease Week
  • amino acid sequences of porcine and human PYY are as follows :
  • porcine PYY YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY (SEQ . ID . NO .
  • the amino acid sequence for dog PYY and rat is the same as porcine PYY.
  • the present invention features novel analogs of peptide YY of the formula:
  • X is a chain of 0-5 amino acids, inclusive, the N- terminal one of which is bonded to R 1 and R 2 ;
  • Y is a chain of 0-4 amino acids, inclusive, the C- terminal one of which is bonded to R 3 and R 4 ;
  • R 1 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), C 1 -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl);
  • C 1 -C 12 alkyl e.g., methyl
  • C 6 -C 18 aryl e.g., phenyl, naphthaleneacetyl
  • C 1 -C 12 acyl e.g., formyl, acetyl, and myristoyl
  • C 7 -C 18 aralkyl e.g., benzyl
  • C 7 -C 18 alkaryl e.g.,
  • R 2 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl,naphthaleneacetyl), C 1 -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g.,benzyl), or C 7 -C 18 alkaryl
  • a 22 is an aromatic amino acid, Ala, Aib, Anb, N-Me-Ala, or is deleted;
  • a 23 is Ser, Thr, Ala, Aib, N-Me-Ser, N-Me-Thr, N
  • Me-Ala or is deleted
  • a 24 is Leu, Ile, Val, Trp, Gly, Aib, Anb, N-Me-Leu, or is deleted;
  • a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or an aryl group), Orn, or is deleted;
  • a 26 is Ala, His, Thr, 3-Me-His, 1-Me-His, ⁇ -pyrozolylalanine, N-Me-His, Arg, Lys, homo- Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or an aryl group), Orn, or is
  • a 27 is an aromatic amino acid other than Tyr
  • a 28 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu;
  • a 29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn;
  • a 30 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu;
  • a 31 is Val, Ile, Trp, Aib, Anb, or N-Me-Val;
  • a 32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp;
  • R 3 is H, C 1 -C 10 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), C 1 -C 10 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl); and
  • R 4 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, naphthaleneacetyl), C 1 -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl), or a pharmaceutically acceptable salt thereof.
  • a 27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or Dip.
  • X is A 17 -A 18 -A 19 -A 20 -A 21 wherein
  • a 17 is Cys, Leu, Ile, Val, Aib, Anb, or N-Me-Leu;
  • a 18 is Cys, Ser, Thr, N-Me-Ser, or N-Me-Thr;
  • a 19 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Orn;
  • a 20 is an aromatic amino acid, or Cys; and A 21 is an aromatic amino acid, Cys, or a
  • Y is A 33 -A 34 -A 35 -A 36 wherein
  • a 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or an aryl group), Cys, or Orn;
  • a 34 is Cys, Gin, Asn, Ala, Gly, N-Me-Gln, Aib, or
  • a 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R(where R is H, a branched or straight chain C 1 -C 10 alkyl group, or an aryl group), Cys, or Orn; and
  • a 36 is an aromatic amino acid, Cys or a
  • the compound has the formula: N- ⁇ -Ac- Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg- Tyr-NH 2 (SEQ. ID. NO. 3), H-Ala-Ser-Leu-Arg-His-Phe-Leu- Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ. ID. NO. 4), N- ⁇ -Ac-Ala-Ser-Leu-Arg-His-Trp-Leu-Asn-Leu-Val-Thr-Arg-Gln- Arg-Tyr-NH 2 (SEQ. ID. NO.
  • N- ⁇ -Ac-Ala-Ser-Leu-Arg-His- Thi-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 SEQ. ID. NO. 6
  • N- ⁇ -Ac-Tyr-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr- Arg-Gln-Arg-Tyr-NH 2 SEQ. ID. NO. 7
  • the N-terminal amino acid is bonded to R 1 and R 2 ;
  • Y is a chain of 0-4 amino acids, inclusive the C-terminal one of which is bonded to R 3 and R 4 ;
  • R 1 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, napthaleneacetyl), C 1 -C 12 acyl (e. g. , formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl);
  • C 1 -C 12 alkyl e.g., methyl
  • C 6 -C 18 aryl e.g., phenyl, napthaleneacetyl
  • C 1 -C 12 acyl e. g. , formyl, acetyl, and myristoyl
  • C 7 -C 18 aralkyl e.g., benzyl
  • C 7 -C 18 alkaryl e.g.,
  • R 2 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, napthaleneacetyl), C 1 -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl (e.g., p-methylphenyl);
  • C 1 -C 12 alkyl e.g., methyl
  • C 6 -C 18 aryl e.g., phenyl, napthaleneacetyl
  • C 1 -C 12 acyl e.g., formyl, acetyl, and myristoyl
  • C 7 -C 18 aralkyl e.g., benzyl
  • C 7 -C 18 alkaryl e.g., p-methyl
  • a 25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or an aryl group), Orn, or is deleted;
  • a 26 is Ala, His, Thr, 3-Me-His, 1-Me-His,
  • a 27 is an aromatic amino acid
  • a 28 is Leu, Ile, Val, Trp, Aib, Anb, or
  • a 29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn;
  • a 30 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu;
  • a 31 is Val, Ile, Trp, Aib, Anb, or N-Me-Val
  • a 32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp;
  • R 3 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl
  • C 1 -C 12 acyl e.g., formyl, acetyl, and myristoyl
  • C 7 -C 18 aralkyl e.g., benzyl
  • C 7 -C 18 alkaryl e.g., benzyl
  • R 4 is H, C 1 -C 12 alkyl (e.g., methyl), C 6 -C 18 aryl (e.g., phenyl, napthaleneacetyl), C 1 -C 12 acyl (e.g., formyl, acetyl, and myristoyl), C 7 -C 18 aralkyl (e.g., benzyl), or C 7 -C 18 alkaryl
  • a 27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or Dip.
  • Y is A 33 -A 34 -A 35 -A 36 wherein
  • a 33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ⁇ -NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Orn;
  • a 34 is Gln, Asn, Ala, Gly, N-Me-Gln, Aib, Cys, or
  • a 35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R (where R is H, a branched or straight chain C 1 -C 10 alkyl group, or C 6 -C 18 aryl group), Cys, or Orn; and
  • a 36 is an aromatic amino acid, Cys, or a
  • the compound has the formula N- ⁇ -Ac-Arg-His-Phe-Leu-Asn- Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH 2 (SEQ. ID. NO. 8).
  • the invention features novel dimeric analogs of peptide YY.
  • the dimer may be formed by either including two peptides of Formula I, two peptides of Formula II, or one peptide of Formula I and one peptide of Formula II.
  • the dimer is formed by utilizing a dicarboxylic acid linker capable of binding to a free amine, either primary or secondary, located within each peptide. See, e.g., R. Vavrek and J. Stewart, Peptides: Structure and Function 381-384 (Pierce Chemical Co. 1983) .
  • suitable dicarboxylic acid linkers are succinic acid, glutamic acid, and phthalic acid.
  • the dimer is formed by utilizing an amino acid linker capable of binding to a free amine group of one peptide and a free carboxyl group of the other peptide.
  • the amino acid linker is a non ⁇ -amino acid.
  • suitable amino acid linkers are amino-caproic acid and amino-valeric acid.
  • the dimer is formed by a disulfide bridge between cysteines located within each peptide. See, e.g., M. Berngtowicz and G. Piatsueda,
  • -NH-CH(R)-CO-N when it is at C-terminus, or -NH-CH(R)- CO- when it is not at the N- or C-terminus, where R denotes the side chain (or identifying group) of an amino acid or its residue.
  • R is -CH 2 COOH for Asp
  • R is -H for Gly
  • R is -CH 2 OH for Ser
  • R is -CH 3 for Ala
  • R is -CH 2 CH 2 CH 2 CH 2 NH 2 for Arg.
  • the amino acid residue is optically active, it is the L-form configuration that is intended unless the D-form is expressly designated.
  • Tic tetrahydroisoquinoline-3-carboxylic acid
  • Aib aminoisobutyric acid
  • the compounds of the present invention can be provided in the form of pharmaceutically acceptable salts.
  • preferred salts are those with therapeutically acceptable organic acids, e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluenesulfonic, trifluoroacetic, or pamoic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids, such as hydrohalic acids, e.g., hydrochloric acid, sulfuric acid, or phosphoric acid and the like.
  • the invention features one of the above compounds and a pharmaceutically acceptable carrier substance in a therapeutic composition capable of decreasing excess intestinal water and electrolyte secretion.
  • the composition is in the form of a liquid, pill, tablet, or capsule for oral administration; a liquid capable of being administered nasally as drops or spray or a liquid for intravenous, subcutaneous, parenteral, intraperitoneal or rectal administration.
  • the therapeutic composition can also be in the form of an oil emulsion or dispersion in
  • a lipophilic salt such as pamoic acid
  • a biodegradable sustained-release composition for subcutaneous or intramuscular
  • the invention features, a method for decreasing excess intestinal water and electrolyte secretion in a mammal, the method comprising administering to the mammal, e.g., a human, a
  • the invention features a method of . regulating cell proliferation in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the composition of the above
  • the method regulates the proliferation of an intestinal cell.
  • the invention also features methods for increasing nutrient transport, regulating lipolysis, and regulating blood flow in a mammal, the methods comprising
  • the compounds of the invention exhibit a broad range of biological activities related to their
  • the compounds are believed to suppress gastrointestinal secretions by direct interaction with epithelial cells or, perhaps, by inhibiting secretion of hormones or neurotransmitters which stimulate intestinal secretion.
  • the compounds of the invention may also control intestinal blood flow which in turn may modulate intestinal hydrostatic
  • the compounds of the invention are especially useful in the treatment of any number of gastrointestinal disorders (see e.g., Harrison 's Principles of Internal Medicine , McGraw-Hill Inc., New York, 12th Ed.) that are associated with excess intestinal electrolyte and water secretion as well as decreased absorption, e.g., infectious (e.g., viral or bacterial) diarrhea,
  • infectious diarrhea examples include, without limitation, acute viral diarrhea, acute bacterial diarrhea (e.g., salmonella, campylobacter, and clostridium or due to protozoal infections), or traveller's diarrhea (e.g., Norwalk virus or rotavirus). Examples of inflammatory diarrhea
  • the peptides of the invention can be used to treat an emergency or life-threatening situation involving a gastrointestinal disorder, e.g., after surgery or due to cholera.
  • the compounds of the invention can be used to treat patients suffering from Acquired Immune Deficiency Syndrome (AIDS),
  • the compounds of the invention are also useful for inhibiting small intestinal fluid and electrolyte
  • the compounds of the invention are advantageous because they are truncated versions of the natural PYY peptide; thus, the shorter peptide not only facilitates easier synthesis and purification of the compounds, but also improves and reduces manufacturing procedures and expenses. Moreover, a shorter PYY compound is
  • FIG. 1 shows a semipreparative reversed phase chromatogram of N- ⁇ -Ac-[Phe 27 ]PYY(22-36) (SEQ. ID. NO. 3) ( «25mg) obtained by HF cleavage.
  • FIG. 2 shows a graph of the inhibition of 125 I- PYY binding to rat jejunal membranes by increasing concentrations of PYY (SEQ. ID. NO. 1), PYY(22-36) (SEQ. ID. NO. 10), [Im-DNP-His 26 ]PYY (SEQ. ID. NO. 9),
  • N- ⁇ -Ac-[N-Me-Tyr 26 ]PYY (22-36) SEQ. ID. NO. 17
  • N- ⁇ -Myristoyl-PYY (22-36) SEQ. ID. NO. 18
  • N- ⁇ - Naphthaleneacetyl-PYY(22-36) SEQ. ID. NO. 19
  • PYY (22-26) SEQ. ID. NO. 10
  • FIGS. 3A-B show the antisecretory effects of PYY (SEQ. ID. NO. 1), PYY(22-36) (SEQ. ID. NO. 10) and analogs up one baseline short circuit current (SCC) in voltage clamped preparation of rat jejunum. Values of changes in SCC are quoted of ⁇ A/0.6cm 2 , mean ⁇ SEM from between 3 and 7 different jejunal preparations. Peptides shown in A and B are denoted by the same symbol as in FIG. 2.
  • FIG. 4 shows a graph of the inhibition of 125 I-PYY binding to rat jejunal membranes by increasing
  • N- ⁇ -Ac- [Phe 27 ]PYY(25-36) (SEQ. ID. NO. 26)
  • N- ⁇ -Ac-[Trp 27 ]PYY(22- 36) (SEQ. ID. NO. 5)
  • N- ⁇ -Ac-[Thi 27 ]PYY(22-36) (SEQ. ID. NO. 6).
  • the peptides of the invention have the general formula recited in the Summary of the Invention above. They all have an aromatic amino acid group at position 27 which is important for both antisecretory activity and utility as antidiarrheal compounds.
  • the peptides of the present invention may be synthesized by any techniques that are known to those skilled in the peptide art. An excellent summary of the many techniques so available may be found in Solid Phase Peptide Synthesis 2nd ed. (Stewart, J.M. and Young, J. D. Pierce Chemical Company, Rockford, IL, 1984).
  • peptides listed in Table 1 and Table 2 were synthesized as follows. Peptide synthesis was performed on an Applie Biosystems Model 430A synthesizer. Amino acid and sequence analyses were carried out using Waters Pico-Tag and Applied Biosystems Model 470A instruments, respectively. Peptides were purified using a Waters Model 600 solvent delivery system equipped with a Model 481 Spectrophotometer and U6K injector according to standard protocols. Peptide masses were determined at the University of Michigan, Protein Chemistry Facility, Ann Arbor, Michigan according to standard methods. All Boc-L-amino acid derivatives, solvents, chemicals and the resins were obtained commercially and used without further purification.
  • MBHA Paramethylbenzhydroxylamine
  • the peptide resin ( ⁇ 1.0 g) was then treated with HF (10 ml) containing p-cresol (-0.8 g) for 1 h at -2 to -4 °C.
  • the HF was evacuated and the residue was
  • Non-specific 125 I-PYY binding was determined in the presence of 1 ⁇ M unlabeled PYY represented 10% of the total binding.
  • the antisecretory effects of the peptides were investigated by measuring the short-circuit current (SCC) in rat jejunal mucosa mounted in a Ussing chamber and automatically voltage clamped as described by Cox et al. (J. Physiol . supra) . Briefly, strips of mucosa were placed between two halves of perspex Ussing chambers (window size, 0.6 cm 2 ) containing oxygenated (95% 0 2 /5% .
  • SCC short-circuit current
  • Fig. 1 shows the RP-HPLC chromatogram of N- ⁇ -Ac-[Phe 27 ]PYY (22-36) (SEQ. ID. NO. 3).
  • the free peptides were further characterized by sequence analysis (see. Table 1 and Table 2). The overall yields of the peptides were in the range of 10% to 30%.
  • hydrophobic groups are known to increase the interaction with the receptors (Balasubramaniam et al. Biochem . Biophys . Res . Comm .
  • N- ⁇ -acetylation of PYY (22-36) increased the receptor affinity four times.
  • Further structure-activity studies with N- ⁇ -Ac-PYY(22-36) (SEQ. ID. NO. 20) revealed that substitution of Tyr 36 with N-Me- Tyr or His 26 with p.Cl-Phe lowers the binding potency.
  • replacement of Tyr 27 with Phe increased the receptor affinity by 28%.
  • the binding of PYY (22-36) SEQ. ID. NO. 10 and several of its analogs were also tested. However, none of these analogs
  • N- ⁇ -myristoyl-PYY (22-36) (SEQ. ID. NO. 18) and N- ⁇ - naphthaleneacetyl-PYY(22-36) (SEQ. ID. NO. 19) analogs, in contrast to their moderate binding potency, exhibited poor antisecretory responses with threshold
  • PYY 100 nM
  • N- ⁇ -myristoyl-PYY (22-36) (SEQ. ID. NO. 18) and N- ⁇ - naphthaleneacetyl-PYY (22-36) (SEQ. ID. NO. 19) analogs inhibited 125 I-PYY binding with moderate potency, but exhibited poor antisecretory responses. This observation suggested that these analogs may be antagonists.
  • Table 2 and Fig. 4 present the IC 50 values for additonal PYY (22-36) (SEQ. ID. NO. 10) and PYY (25-36) analogs. Based on the results presented in Table 2 the analogs in this series exhibited the following order of potency:
  • N- ⁇ -Ac-[Tic 27 ]PYY(22-36) (SEQ. ID. NO. 25) ⁇ N- ⁇ -Ac- [Bip 27 ]PYY (22-36) (SEQ. ID. NO. 22) ⁇ N- ⁇ -Ac- [Nal 27 ]PYY (22-36) (SEQ. ID. NO. 23) ⁇ N- ⁇ -Ac- [Bth 27 ]PYY(22-36) (SEQ. ID. NO. 21) ⁇ N- ⁇ -Ac- [Phe 27 ]PYY(22-36) (SEQ. ID. NO. 3) ⁇ N- ⁇ -Ac-[Phe 27 ]PYY(25- 36) (SEQ.
  • NPY/PYY receptors characterized to date have been broadly classified into Y-1, Y-2 and Y-3 subtypes
  • Y-1 and Y-2 receptors exhibit a preference for PYY over NPY, and more significantly C-terminal fragments of NPY and PYY are effective only at the Y-2 subtype.
  • N- ⁇ - Ac-[Phe 27 ]PYY(22-36) (SEQ. ID. NO. 3), N- ⁇ -Ac- [Trp 27 ]PYY(22-36) (SEQ. ID. NO. 24), N- ⁇ -Ac-[Phe 27 ]PYY(25- 36) (SEQ. ID. NO. 3), N- ⁇ -Ac-[Thi 27 ]PYY(22-36) (SEQ. ID. NO. 6) or derivative thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound or
  • compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally (e.g., by. suppositories or washings),
  • transdermally e.g., skin electroporation
  • inhalation e.g., by aerosol
  • inhalation e.g., by aerosol
  • solid, liquid or gaseous dosage including tablets and suspensions.
  • the administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum.
  • the method of the present invention is practiced when relief of symptoms is specifically
  • the method of the present invention is effectively practiced as continuous or prophylactic treatment.
  • compositions hereof can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, suppositories, powders,
  • enterically coated or other protected formulations e.g. binding on ion-exchange resins or packaging in lipid- protein vesicles
  • sustained release formulations solutions, suspensions, elixirs, aerosols, and the like.
  • the carrier can be selected from the various oils
  • liquid carriers including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic with the blood) for
  • formulation for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile.
  • suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, talc, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
  • the compositions may be subjected to conventional pharmaceutical additives such as
  • compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
  • a typical administration is oral administration or parenteral administration.
  • the daily dose in the case of oral administration is typically in the range of 0.1 to 100 mg/kg body weight, and the daily dose in the case of parenteral administration is typically in the range of 0.001 to 50 mg/kg body weight.
  • the therapeutic agents be relatively non-toxic, non-antigenic and non-irritating at the levels in actual use.

Abstract

The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.

Description

ANALOGS OF PEPTIDE YY AND USES THEREOF
Statement as To Federally Sponsored Research This invention was made in part with Government funding and the Government therefore has certain rights in the invention.
Background of the Invention
This invention relates to peptide derivatives which are useful as therapeutic agents in the treatment of gastroenterological disorders.
Peptide YY (PYY) is a 36-residue peptide amide isolated originally from porcine intestine, and localized in the endocrine cells of the gastrointestinal tract and pancreas (Tatemoto et al. Proc. Natl . Acad. Sci . 79:2514, 1982) . Peptide YY has N-terminal and C-terminal tyrosine amides; accordingly, these two tyrosines give PYY its name (Y represents the amino acid tyrosine in the peptide nomenclature). In addition PYY shares a number of central and peripheral regulatory roles with its
homologous peptide neuropeptide Y (NPY), which was originally isolated from porcine brain (Tatemoto, Proc . Natl . Acad . Sci . 79:5485, 1982). In contrast with the cellular location of PYY, NPY is present in submucous and myenteric neurons which innervate the mucosal and smooth muscle layers, respectively (Ekblad et al. Neuroscience 20:169, 1987). Both PYY and NPY are be Ileved to inhibit gut motility and blood flow (Laburthe, Trends Endocrinol . Metab . 1:168, 1990), and they are also thought to
attenuate basal (Cox et al. Br. J. Pharmacol . 101:247, 1990; Cox et al. J. Physiol . 398:65, 1988; Cox et al.
Peptides 12:323, 1991; Friel et al. Br. J. Pharmacol .
88:425, 1986) and secretagogue-induced intestinal
secretion in rats (Lundberg et al. Proc. Natl . Acad . Sci USA 79:4471, 1982; Playford et al. Lancet 335:1555, 1990) and humans (Playford et al. supra) , as well as stimulate net absorption (MacFadyen et al. Neuropeptides 7:219, 1986). Furthermore, plasma PYY levels have been reported to be elevated in several diseases that cause diarrhea (Adrian et al. Gastroenterology 89:1070, 1985). Taken together, these observations suggest that PYY and-NPY are released into the circulation after a meal (Adrian et al. Gastroenterology 89:1070, 1985; Balasubramaniam et al. Neuropeptides 14:209, 1989), and thus may play a
physiological role in regulating intestinal secretion and absorption, serving as natural inhibitors of diarrhea.
A high affinity PYY receptor system which exhibits a slightly higher affinity for PYY than NPY has been characterized in rat intestinal epithelia (Laburthe et al. Endocrinology 118:1910, 1986; Laburthe, Trends
Endocrinol . Metab. supra) and shown to be negatively coupled to adenylate cyclase (Servin et al. Endocrinology 124:692, 1989). Consistently, PYY exhibited greater antisecretory potency than NPY in voltage clamped
preparations of rat small intestine (Cox et al. J.
Physiol . supra) , while
C-terminal fragments of NPY were found to be less
effective in their antisecretory potency than PYY (Cox et al. Br. J. Pharmacol , supra) . Structure-activity studies using several partial sequences have led to the
identification of PYY(22-36) as the active site for interacting with intestinal PYY receptors (Balsubramaniam et al. Pept . Res . 1:32, 1988).
In addition, PYY has been implicated in a number of physiological activities including nutrient uptake (see, e.g., Bilcheik et al. Digestive Disease Week
506:623, 1993), cell proliferation (see, e.g., Laburthe, Trends Endocrinol . Metab . 1:168, 1990; Voisin et al. J. Biol . Chem, 1993), lipolysis (see, e.g.. Valet et al., J. Clin . Invest . 85:291, 1990), and vasoconstriction (see , e . g. , Lundberg et al . , Proc . Natl . Acad . SCi . , USA 79 : 4471 , 1982 ) .
The amino acid sequences of porcine and human PYY are as follows :
porcine PYY YPAKPEAPGEDASPEELSRYYASLRHYLNLVTRQRY (SEQ . ID . NO .
1)
human PYY YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY (SEQ . ID . NO .
2)
The amino acid sequence for dog PYY and rat is the same as porcine PYY.
Summary of the Invention
In one aspect, the present invention features novel analogs of peptide YY of the formula:
R1 R3
Figure imgf000005_0001
R2-X-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-Y-R4 wherein
X is a chain of 0-5 amino acids, inclusive, the N- terminal one of which is bonded to R1 and R2;
Y is a chain of 0-4 amino acids, inclusive, the C- terminal one of which is bonded to R3 and R4;
R1 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl, naphthaleneacetyl), C1-C12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl (e.g., p-methylphenyl);
R2 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl,naphthaleneacetyl), C1-C12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g.,benzyl), or C7-C18 alkaryl
(e.g., p-methylphenyl);
A22 is an aromatic amino acid, Ala, Aib, Anb, N-Me-Ala, or is deleted;
A23 is Ser, Thr, Ala, Aib, N-Me-Ser, N-Me-Thr, N
Me-Ala, or is deleted;
A24 is Leu, Ile, Val, Trp, Gly, Aib, Anb, N-Me-Leu, or is deleted;
A25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Orn, or is deleted;
A26 is Ala, His, Thr, 3-Me-His, 1-Me-His, β-pyrozolylalanine, N-Me-His, Arg, Lys, homo- Arg, diethyl-homo-Arg, Lys-ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Orn, or is
deleted;
A27 is an aromatic amino acid other than Tyr;
A28 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu; A29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn; A30 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu; A31 is Val, Ile, Trp, Aib, Anb, or N-Me-Val;
A32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp;
R3 is H, C1-C10 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl, naphthaleneacetyl), C1-C10 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl (e.g., p-methylphenyl); and
R4 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl, naphthaleneacetyl), C1-C12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl (e.g., p-methylphenyl), or a pharmaceutically acceptable salt thereof.
In preferred embodiments. A27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or Dip. In preferred embodiments X is A17-A18-A19-A20-A21 wherein
A17 is Cys, Leu, Ile, Val, Aib, Anb, or N-Me-Leu; A18 is Cys, Ser, Thr, N-Me-Ser, or N-Me-Thr;
A19 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), Cys, or Orn;
A20 is an aromatic amino acid, or Cys; and A21 is an aromatic amino acid, Cys, or a
pharmaceutically acceptable salt thereof. In yet other preferred embodiments, Y is A33-A34-A35-A36 wherein
A33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Cys, or Orn;
A34 is Cys, Gin, Asn, Ala, Gly, N-Me-Gln, Aib, or
Anb;
A35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R(where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Cys, or Orn; and
A36 is an aromatic amino acid, Cys or a
pharmaceutically acceptable salt thereof.
Preferably, the compound has the formula: N-α-Ac- Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg- Tyr-NH2 (SEQ. ID. NO. 3), H-Ala-Ser-Leu-Arg-His-Phe-Leu- Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 4), N- α-Ac-Ala-Ser-Leu-Arg-His-Trp-Leu-Asn-Leu-Val-Thr-Arg-Gln- Arg-Tyr-NH2 (SEQ. ID. NO. 5), N-α-Ac-Ala-Ser-Leu-Arg-His- Thi-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 6) , N-α-Ac-Tyr-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr- Arg-Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 7) or a
pharmaceutically acceptable salt thereof.
In another aspect the invention features novel analogs of peptide YY of the formula: R1 R3
Figure imgf000008_0001
R2-A25-A26-A27-A28-A29-A30-A31-A32-Y-R4 wherein
the N-terminal amino acid is bonded to R1 and R2;
Y is a chain of 0-4 amino acids, inclusive the C-terminal one of which is bonded to R3 and R4;
R1 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl, napthaleneacetyl), C1-C12 acyl (e. g. , formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl (e.g., p-methylphenyl);
R2 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl, napthaleneacetyl), C1-C12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl (e.g., p-methylphenyl);
A25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Orn, or is deleted;
A26 is Ala, His, Thr, 3-Me-His, 1-Me-His,
β-pyrozolylalanine, N-Me-His, Arg, Lys, homo- Arg, diethyl-homo-Arg, Lys-ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Orn, or is
deleted;
A27 is an aromatic amino acid;
A28 is Leu, Ile, Val, Trp, Aib, Anb, or
N-Me-Leu;
A29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn;
A30 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu;
A31 is Val, Ile, Trp, Aib, Anb, or N-Me-Val; A32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp; R3 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl
(e.g., phenyl, napthaleneacetyl), C1-C12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl
(e.g., p-methylphenyl); and
R4 is H, C1-C12 alkyl (e.g., methyl), C6-C18 aryl (e.g., phenyl, napthaleneacetyl), C1-C12 acyl (e.g., formyl, acetyl, and myristoyl), C7-C18 aralkyl (e.g., benzyl), or C7-C18 alkaryl
(e.g., p-methylphenyl), or a pharmaceutically acceptable salt thereof.
In preferred embodiments A27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or Dip.
In preferred embodiments Y is A33-A34-A35-A36 wherein
A33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), Cys, or Orn;
A34 is Gln, Asn, Ala, Gly, N-Me-Gln, Aib, Cys, or
Anb;
A35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- e-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), Cys, or Orn; and
A36 is an aromatic amino acid, Cys, or a
pharmaceutically acceptable salt thereof. Preferably, the compound has the formula N-α-Ac-Arg-His-Phe-Leu-Asn- Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 8).
In another aspect, the invention features novel dimeric analogs of peptide YY. The dimer may be formed by either including two peptides of Formula I, two peptides of Formula II, or one peptide of Formula I and one peptide of Formula II. In one embodiment, the dimer is formed by utilizing a dicarboxylic acid linker capable of binding to a free amine, either primary or secondary, located within each peptide. See, e.g., R. Vavrek and J. Stewart, Peptides: Structure and Function 381-384 (Pierce Chemical Co. 1983) . Examples of suitable dicarboxylic acid linkers are succinic acid, glutamic acid, and phthalic acid. In other embodiments, the dimer is formed by utilizing an amino acid linker capable of binding to a free amine group of one peptide and a free carboxyl group of the other peptide. Preferably, the amino acid linker is a non α-amino acid. Examples of suitable amino acid linkers are amino-caproic acid and amino-valeric acid. In yet another embodiment, the dimer is formed by a disulfide bridge between cysteines located within each peptide. See, e.g., M. Berngtowicz and G. Piatsueda,
Peptides: structure and Function 233-244 (Pierce Chemical Co. 1985); F. Albericio, et al., Peptides 1990. 535
(ESCOM 1991).
The symbol X, Y, Z; A22, A23, A24, and the like; and Ser, Leu or the like, as found in a peptide sequence herein stands for an amino acid residue, i.e.,
=N-CH(R)-CO- when it is at the N-terminus, or
-NH-CH(R)-CO-N= when it is at C-terminus, or -NH-CH(R)- CO- when it is not at the N- or C-terminus, where R denotes the side chain (or identifying group) of an amino acid or its residue. For example, R is -CH2COOH for Asp, R is -H for Gly, R is -CH2OH for Ser, R is -CH3 for Ala and R is -CH2CH2CH2CH2NH2 for Arg. Also, when the amino acid residue is optically active, it is the L-form configuration that is intended unless the D-form is expressly designated.
As set forth above and for convenience in
describing this invention, the conventional and
nonconventional abbreviations for the various amino acids are used. They are familiar to those skilled in the art; but for clarity are listed below. All peptide sequences mentioned herein are written according to the usual convention whereby the N-terminal amino acid is on the left and the C-terminal amino acid is on the right. A short line between two amino acid residues indicates a peptide bond.
Asp = D = Aspartic Acid
Ala = A = Alanine
Arg = R = Arginine
Asn = N = Asparagine
Cys = C = Cysteine
Gly = G = Glycine
Glu = E = Glutamic Acid
Gin = Q = Glutamine
His = H = Histidine
He = I = Isoleucine
Leu = L = Leucine
Lys = K = Lysine
Met = M = Methionine
Phe = F = Phenylalanine
Pro = P = Proline
Ser = S = Serine
Thr = T = Threonine
Trp = W = Tryptophan
Tyr = Y = Tyrosine
Val = V = Valine
Orn = Ornithine
Nal = 2-napthylalanine
Thi = 2-thienylalanine
Pep = 4-chlorophenylalanine
Bth = 3-benzothienyalanine
Bip = 4,4'-biphenylalanine
Tic = tetrahydroisoquinoline-3-carboxylic acid Aib = aminoisobutyric acid
Anb = α-aminonormalbutyric acid
Dip = 2,2-diphenylalanine
Thz = 4-Thiazolylalanine
The compounds of the present invention can be provided in the form of pharmaceutically acceptable salts. Examples of preferred salts are those with therapeutically acceptable organic acids, e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, salicylic, methanesulfonic, toluenesulfonic, trifluoroacetic, or pamoic acid, as well as polymeric acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids, such as hydrohalic acids, e.g., hydrochloric acid, sulfuric acid, or phosphoric acid and the like.
In another aspect, the invention features one of the above compounds and a pharmaceutically acceptable carrier substance in a therapeutic composition capable of decreasing excess intestinal water and electrolyte secretion.
In preferred embodiments, the composition is in the form of a liquid, pill, tablet, or capsule for oral administration; a liquid capable of being administered nasally as drops or spray or a liquid for intravenous, subcutaneous, parenteral, intraperitoneal or rectal administration. The therapeutic composition can also be in the form of an oil emulsion or dispersion in
conjunction with a lipophilic salt such as pamoic acid, or in the form of a biodegradable sustained-release composition for subcutaneous or intramuscular
administration. For maximum efficacy, zero-order release is desired.
In another aspect the invention features, a method for decreasing excess intestinal water and electrolyte secretion in a mammal, the method comprising administering to the mammal, e.g., a human, a
therapeutically effective amount of the above mentioned compounds.
In addition, the invention features a method of . regulating cell proliferation in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the composition of the above
mentioned compounds. Preferably, the method regulates the proliferation of an intestinal cell.
The invention also features methods for increasing nutrient transport, regulating lipolysis, and regulating blood flow in a mammal, the methods comprising
administering to the mammal a therapeutically effective amount of the above mentioned compositions.
The compounds of the invention exhibit a broad range of biological activities related to their
antisecretory and antimotility properties. The compounds are believed to suppress gastrointestinal secretions by direct interaction with epithelial cells or, perhaps, by inhibiting secretion of hormones or neurotransmitters which stimulate intestinal secretion. The compounds of the invention may also control intestinal blood flow which in turn may modulate intestinal hydrostatic
pressure in favor of net water absorption.
The compounds of the invention are especially useful in the treatment of any number of gastrointestinal disorders (see e.g., Harrison 's Principles of Internal Medicine , McGraw-Hill Inc., New York, 12th Ed.) that are associated with excess intestinal electrolyte and water secretion as well as decreased absorption, e.g., infectious (e.g., viral or bacterial) diarrhea,
inflammatory diarrhea, short bowel syndrome, or the diarrhea which typically occurs following surgical procedures, e.g., ileostomy. Examples of infectious diarrhea include, without limitation, acute viral diarrhea, acute bacterial diarrhea (e.g., salmonella, campylobacter, and clostridium or due to protozoal infections), or traveller's diarrhea (e.g., Norwalk virus or rotavirus). Examples of inflammatory diarrhea
include, without limitation, malabsorption syndrome, tropical spue, chronic pancreatitis, Crohn's disease, diarrhea, and irritable bowel syndrome. It has also been discovered that the peptides of the invention can be used to treat an emergency or life-threatening situation involving a gastrointestinal disorder, e.g., after surgery or due to cholera. Furthermore, the compounds of the invention can be used to treat patients suffering from Acquired Immune Deficiency Syndrome (AIDS),
especially during cachexia.
The compounds of the invention are also useful for inhibiting small intestinal fluid and electrolyte
secretion, augmenting nutrient transport -- as well as increasing cell proliferation -- in the gastrointestinal tract, regulating lipolysis in, e.g, adipose tissue, and regulating blood flow in a mammal.
The compounds of the invention are advantageous because they are truncated versions of the natural PYY peptide; thus, the shorter peptide not only facilitates easier synthesis and purification of the compounds, but also improves and reduces manufacturing procedures and expenses. Moreover, a shorter PYY compound is
advantageous because such peptides will interact solely with PYY receptors and not with homologous receptors such as NPY Y1 and Y3; thus, minimizing unwanted agonist or antagonist side reactions.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims. Detailed Description
The drawings will first be described.
Drawings
FIG. 1 shows a semipreparative reversed phase chromatogram of N-α-Ac-[Phe27]PYY(22-36) (SEQ. ID. NO. 3) («25mg) obtained by HF cleavage. Conditions: Vydac C18 semipreparative column (250 X 10mm, 300 Å pore size, 10 micron particle size); flow rate 4.7 ml/min; fractions 1, 2, 3, and 4 were collected and analyzed by analytical chromatography. The homogeneous fractions (1-3) were combined and dried in a speed vac.
FIG. 2 shows a graph of the inhibition of 125I- PYY binding to rat jejunal membranes by increasing concentrations of PYY (SEQ. ID. NO. 1), PYY(22-36) (SEQ. ID. NO. 10), [Im-DNP-His26]PYY (SEQ. ID. NO. 9),
[Ala32]PYY(22-36) (SEQ. ID. NO. 11), [Ala23'32]PYY(22-36) (SEQ. ID. NO. 12), [Glu28]PYY (22-36) (SEQ. ID. NO. 13), N- α-Ac-PYY(22-36) (SEQ. ID. NO. 14), N-Q-Ac-[p.Cl- Phe28]PYY(22-36) (SEQ. ID. NO. 15), N-α-Ac-[Glu26]PYY(22- 36) (SEQ. ID. NO. 16), N-α-Ac-[Phe27]PYY(22-36) (SEQ. ID. NO. 3), N-α-Ac-[N-Me-Tyr26]PYY (22-36) (SEQ. ID. NO. 17), N- α-Myristoyl-PYY (22-36) (SEQ. ID. NO. 18), N-α- Naphthaleneacetyl-PYY(22-36) (SEQ. ID. NO. 19), and PYY (22-26) (SEQ. ID. NO. 10).
FIGS. 3A-B show the antisecretory effects of PYY (SEQ. ID. NO. 1), PYY(22-36) (SEQ. ID. NO. 10) and analogs up one baseline short circuit current (SCC) in voltage clamped preparation of rat jejunum. Values of changes in SCC are quoted of μA/0.6cm2, mean ±SEM from between 3 and 7 different jejunal preparations. Peptides shown in A and B are denoted by the same symbol as in FIG. 2.
FIG. 4 shows a graph of the inhibition of 125I-PYY binding to rat jejunal membranes by increasing
concentrations of PYY, N-α-Ac-PYY (22-36) (SEQ. ID. NO. 14), N-α-Ac-[Tic27]PYY (22-36) (SEQ. ID. NO. 25), N-α-Ac- [Bip27]PYY(22-36) (SEQ. ID. NO. 22), N-α-Ac-[Nal27]PYY (22- 36) (SEQ. ID. NO. 23), N-α-Ac-[Bth27]PYY(22-36) (SEQ. ID. NO. 21), N-α-Ac-[Phe27]PYY (22-36) (SEQ. ID. NO. 3), N-α-Ac- [Phe27]PYY(25-36) (SEQ. ID. NO. 26), N-α-Ac-[Trp27]PYY(22- 36) (SEQ. ID. NO. 5), and N-α-Ac-[Thi27]PYY(22-36) (SEQ. ID. NO. 6).
There now follows a description of the synthesis, analysis for biological efficacy and use of the preferred embodiments of the invention. In order to determine the structural requirements necessary to elicit antisecretory effects, several analogs of the PYY active site, PYY(22- 36), were synthesized and their binding and antisecretory potencies in rat jejunum were compared.
We now describe the structure, synthesis, and use of preferred embodiments of the invention.
STRUCTURE
The peptides of the invention have the general formula recited in the Summary of the Invention above. They all have an aromatic amino acid group at position 27 which is important for both antisecretory activity and utility as antidiarrheal compounds.
SYNTHESIS
The peptides of the present invention may be synthesized by any techniques that are known to those skilled in the peptide art. An excellent summary of the many techniques so available may be found in Solid Phase Peptide Synthesis 2nd ed. (Stewart, J.M. and Young, J. D. Pierce Chemical Company, Rockford, IL, 1984).
The peptides listed in Table 1 and Table 2 were synthesized as follows. Peptide synthesis was performed on an Applie Biosystems Model 430A synthesizer. Amino acid and sequence analyses were carried out using Waters Pico-Tag and Applied Biosystems Model 470A instruments, respectively. Peptides were purified using a Waters Model 600 solvent delivery system equipped with a Model 481 Spectrophotometer and U6K injector according to standard protocols. Peptide masses were determined at the University of Michigan, Protein Chemistry Facility, Ann Arbor, Michigan according to standard methods. All Boc-L-amino acid derivatives, solvents, chemicals and the resins were obtained commercially and used without further purification.
Paramethylbenzhydroxylamine (MBHA) resin (0.45 mmol, -NH2) was placed in the reaction vessel of the peptide synthesizer and the protected amino acid
derivatives were sequentially coupled using the program provided by the manufacturers modified to incorporate a double coupling procedure (see, e.g., Balasubramaniam et al., Peptide Research 1: 32, 1988). All amino acids were coupled using 2.2 equivalents of preformed symmetrical anhydrides. Arg, Gin and Asn, however, were coupled as preformed
1-hydroxybenzotriazole (HOBT) esters to avoid side reactions. At the end of the synthesis, the N-α-Boc group was removed and in some instances the free α-NH2 was acetylated by reaction with acetic anhydride (2 equivalents) and diisopropyl ethylamine until a negative ninhydrin test was obtained (Anal. Biochem. 34:595,
1970). The peptide resin (~1.0 g) was then treated with HF (10 ml) containing p-cresol (-0.8 g) for 1 h at -2 to -4 °C. The HF was evacuated and the residue was
transferred to a fritted filter funnel with diethyl ether, washed repeatedly with diethyl ether, extracted with acetic acid (2 X 15 ml) and lyophilized. The crude peptides thus obtained were purified by semipreparative RP-HPLC as shown in Fig. 1.
Examples of the synthesized nalogs are: [i m--NP-His26) PYY
YPAKPEAPGEDASPEELSRYYASLR [im-DNP-His26] YLNLVTRORY-NH2 (SEQ. ID No. 9)
PYY(22-36)
A S L R H Y L N L V T R Q R Y-NH2 (SEQ. ID No. 10) [Ala32] PYY
A S L R H Y L N L V [Ala] R Q R Y-NH2 (SEQ. ID No. 11 )
[A I a23'32] PYY
A [Ala] L R H Y L N L V [Ala] R Q R Y-NH2 (SEQ. ID No. 12)
[Glu28] PYY(22-36)
A S L R H Y [Glu] N L V T R Q R Y-NH2 (SEQ. ID No. 13)
N-α-Ac-PYY(22-36)
N-α-Ac-A S L R H Y L N L V T R Q R Y-NH2 (SEQ. ID No. 14)
N-α-Ac [p.Cl . Phe26] PYY
N-α-Ac-A S L R [p.Cl . Phe26) Y L N L V T R Q R Y-NH2 (SEQ. ID No. 15) N-α-Ac [Glu28]PYY
N-α-Ac-A S L R H Y [Glu] N L V T R Q R Y-NH2 (SEQ. ID No. 16)
N-α-Ac [Phe27] PYY
N-α-Ac-A S L R H [Phe] E N L V T R Q R [N-Me-Tyr] -NH2 (SEQ. ID No. 3)
N-α-Ac [N-Me-Tyr36] PYY
N-α-Ac-A S L R H Y E N L V T R Q R [N-Me-Tyr] -NH2 (SEQ. ID No. 17)
N-α- myristoyl-PYY(22-36)
N-α-myristoyl-A S L R H Y L N L V T R Q R Y-NH2 (SEQ. ID No. 18)
N-α-naphthaleneacetyl-PYY(22-36)
N-α-naphthaleneacetyl -A S L R H Y L N L V T R O R Y-NH2 (SEQ. ID No. 19) N-α-Ac [Phe27] PYY
N-α-Ac-A S L R H [Phe] E N L V T R Q R [N-Me-Tyr] -NH2 (SEQ. ID No. 3)
N-α-Ac-PYY(22-36)
N-α-Ac-A S L R H Y L N L V T R Q R Y-NH2 (SEQ. ID No. 20)
N-α-Ac- [Bth27]PYY(22-36)
N-α-Ac-A S L R H [Bth] L N L V T R Q R Y-NH2 (SEQ. ID No. 21 )
N-α-Ac- [Bip27] PYY(22-36)
N -α-Ac-A S L R H [Bip] L N L V T R Q R Y-NH2 (SEQ. ID No. 22)
N-α-Ac- [Nal27]PYY(22-36)
N-α-Ac-A S L R H [Nal] L N L V T R Q R Y-NH2 (SEQ. ID No. 23) N-α-Ac- [Trp27]PYY(22-36)
N-α-Ac-A S L R H [Trp] L N L V T R Q R Y-NH2 (SEQ. ID No. 5)
N-α-Ac- [Thi27]PYY(22-36)
N-α-Ac-A S L R H [Thi] L N L V T R Q R Y-NH2 (SEQ. ID No. 6)
N-α-Ac- [Tic27] PYY(22-36)
N-α-Ac-A S L R H [Tic] L N L V T R Q R Y-NH2 (SEQ. ID No. 25)
N-α-Ac- [Phe27] PYY(25-36)
N-α-Ac-H [Phe] L N L V T R Q R Y-NH 2 (SEQ. ID No. 26)
N-α-Ac- [Phe27,Thi36) PYY(22-36)
N-α-Ac-A S L R H [Phe] L N L V T R Q R [Thi] -NH2 (SEQ. ID No. 27) N-α-Ac- [Thz26,Phe27]PYY(22-36)
N-α-Ac-A S L R [Thz] [Phe] L N L V T R Q R Y-NH2 (SEQ. ID No. 28)
N-α-Ac- [Pep27] PYY(22-36) N-α-Ac-A S L R H [Pep] L N L V T R Q R Y-NH2 (SEQ. ID No. 29)
N-α-Ac- [Phe22'27]PYY(22-36)
N-α-Ac- [Phe] S L R H [Phe] L N L V T R Q R Y-NH2 (SEQ. ID No. 30)
N-α-Ac- [Tyr22,Phe27) PYY(22-36)
N-α-Ac- [Tyr] S L R H [Phe] L N L V T R O R Y-NH2 (SEQ. ID No. 7)
N-α-Ac- [Trp28)PYY(22-36)
N-α-Ac- A S L R H Y [Trp] N L V T R Q R Y-NH2 (SEQ. ID No. 31 )
N-α-Ac- [Trp30]PYY(22-36)
N-α-Ac- A S L R H Y L N [Trp] V T R Q R Y-NH2 (SEQ. ID No. 32) N-α-Ac- [Ala26,Phe27]PYY(22-36)
N-α-Ac- A S L R [Ala] [Phe] L N L V T R Q R Y-NH2 (SEQ. ID No. 33)
N-α-Ac- [Bth27]PYY(22-36)
N-α-Ac- A S L R H [Bth] L N L V T R Q R Y-NH 2 (SEQ. ID No. 34)
N-α-Ac- [Phe27]PYY(22-36)
N-α-Ac- A S L R H [Phe] L N L V T R Q R Y-NH2 (SEQ. ID No. 35)
N-α-Ac- [Phe27'36]PYY(22-36)
N-α-Ac- A S L R H [Phe] L N L V T R Q R [Phe] -NH2 (SEQ. ID No. 36)
N-α-Ac- [Phe27, D-Trp32]PYY(22-36)
N-α-Ac- A S L R H [Phe] L N L V [D-Trp] R Q R Y-NH2 (SEQ. ID No. 37}
ANALYSIS
Binding Studies
Preparation of 125I-PYY labeled only at Tyr36 and rat jejunal epithelial plasma membranes were performed according to standard methods (see, e.g., Laburthe et al. Endocrinology, supra ; Servin et al. supra ; Voisin et al. Ann . N. Y. Acad . Sci . 611:343, 1990). Binding
experiments were conducted in a total volume of 0.25 ml 60 mM HEPES buffer, pH 7, containing 2% BSA, 0.1%
bacitracin, 5 mM MgCl2 and 0.05 nM 125I-PYY with or without competing peptides. Bound and free peptides were separated by centrifugation at 20,000 X g for 10 min.
Non-specific 125I-PYY binding was determined in the presence of 1 μM unlabeled PYY represented 10% of the total binding.
Short Circuit Current Measurements
The antisecretory effects of the peptides were investigated by measuring the short-circuit current (SCC) in rat jejunal mucosa mounted in a Ussing chamber and automatically voltage clamped as described by Cox et al. (J. Physiol . supra) . Briefly, strips of mucosa were placed between two halves of perspex Ussing chambers (window size, 0.6 cm2) containing oxygenated (95% 02/5% . CO2) Krebs-Henseleit solution (NaCl, 117 mM, KCl 4.7 mM, CaCl2, 2.5 mM; MgSO4 1.2 mM, NaHCO3 24.8 mM and glucose 11.1 mM), pH 7.4, 37°C. Routinely, four preparations of jejunum were obtained from each animal and these
exhibited comparable potential differences and SCC, but they were not paired. Preparations were automatically voltage clamped using a W-P dual voltage clamp and the SCC displayed continuously on pen recorders. Once a stable baseline SCC was reached, peptides were added to the basolateral reservoir only, and cumulative
concentration-response profiles constructed.
Data Analyses
All points in the binding experiments are the mean of at least three experiments performed in duplicate.
For clarity, the SEMs in the binding experiments are not shown in Fig. 2, but were less than 10%. Values of changes in SCC are quoted as μA/0.6cm2 mean ± 1 SEM from between 3 and 7 different preparations. EC50 values were calculated from pooled cumulative concentration - response curves using an iterative curve fitting program. Comparison of data groups (SCC recordings) were made using unpaired Student's t-tests where a p value <0.5 was considered statistically significant.
There now follows the results of the biological activities of the compounds of the invention (see Table 1 and Table 2). As described below, the tested compounds were assayed for purity and for their binding and
antisecretory potencies in rat jejunum.
Purified peptides were found to be > 96%
homogeneous by analytical reversed phase chromatography and, in addition, had the expected amino acid composition and masses. For example. Fig. 1 shows the RP-HPLC chromatogram of N-α-Ac-[Phe27]PYY (22-36) (SEQ. ID. NO. 3). The free peptides were further characterized by sequence analysis (see. Table 1 and Table 2). The overall yields of the peptides were in the range of 10% to 30%.
PYY, [im-DNP-His26]PYY (SEQ. ID. NO. 9) and the analogs of PYY(22-36) (SEQ. ID. NO. 10) displaced 125I-PYY bound to rat jejunal epithelial plasma membranes in a concentration-dependent manner. Although [im-DNP- His26]PYY (SEQ. ID. NO. 9) and PYY(22-36) (SEQ. ID. NO. 10) were 20-times less potent than PYY based on IC50 values, they displayed the same maximal response as the intact hormone (Fig. 2, Table 1). Substitution of Thr32 with Ala as in [Ala32]PYY(22-36) (SEQ. ID. NO. 11) resulted in the lowering of the binding potency while the
replacement of both Ser23 and Thr32 with Ala further reduced the receptor affinity. Also, introduction of a negative charge at position 28 without altering the helicity as in [Glu28]PYY(22-36) (SEQ. ID. NO. 13)
decreased the binding possibly due to the disruption of the ionic interactions. Since the hydrophobic groups are known to increase the interaction with the receptors (Balasubramaniam et al. Biochem . Biophys . Res . Comm .
137:1041, 1986), the binding of a N-α-myristoyl- and N-α- naphthaleneacetyl-derivatives of PYY (22-36) was also determined. Both these analogs exhibited slightly lower binding affinity than PYY(22-36) (SEQ. ID. NO. 10)
possibly due to increased steric hinderance. On the other hand, N-α-acetylation of PYY (22-36) (SEQ. ID. NO. 14) increased the receptor affinity four times. Further structure-activity studies with N-α-Ac-PYY(22-36) (SEQ. ID. NO. 20) revealed that substitution of Tyr36 with N-Me- Tyr or His26 with p.Cl-Phe lowers the binding potency. However, replacement of Tyr27 with Phe increased the receptor affinity by 28%. As a control, the binding of PYY (22-36) (SEQ. ID. NO. 10) and several of its analogs were also tested. However, none of these analogs
inhibited the binding of 125I-PYY even at 10 μM.
In mucosal preparations of rat jejunum PYY (22-36). (SEQ. ID. NO. 10) analogs reduced the baseline SCC in a concentration dependent manner (Fig. 3A and B) and calculated EC50 values are listed in Table 1. The PYY(22- 36) (SEQ. ID. NO. 10) analogs were generally less potent as antisecretory agents than as inhibitors of binding. The order of analog potency was similar to that from binding studies with two notable exceptions, namely N-α- myristoyl-PYY (22-36) (SEQ. ID. NO. 18) and N-α- naphthaleneacetyl-PYY(22-36) (SEQ. ID. NO. 19). N-α- acetylation and substitution of Tyr27 with Phe increased the antisecretory potency of PYY (22-36) and this analog, N-α-Ac-[Phe27] PYY(22-36) (SEQ. ID. NO. 3), was only 9- times less potent than the intact hormone. Furthermore, there was no significant difference between the maximal inhibitory responses, these being - 12.6±2.4 and - 12.0±1.3μ A/0.6cm2 for PYY (440 nM, n = 6) (SEQ. ID. NO. 1) and N-α-Ac-[Phe27] PYY(22-36) (1.4 μM, n = 7) (SEQ. ID.NO. 3), respectively.
TABLE 1: Comparison of the binding and antisecretory potencies of PYY, PYY fragments and their analogs
Figure imgf000023_0001
a: isocratic, 27% CH3CN containing 0.1X TFA; b: mean of three separate experiments;
c: isocratic, 32% CH3CN containing 0.1X TFA; d: from reference 10; n.d.: not determined
N-α-myristoyl-PYY (22-36) (SEQ. ID. NO. 18) and N-α- naphthaleneacetyl-PYY(22-36) (SEQ. ID. NO. 19) analogs, in contrast to their moderate binding potency, exhibited poor antisecretory responses with threshold
concentrations of about 20nM and EC50 values greater than 2 and 30 μM respectively. After a cumulative
concentration of 7.4 μM, N-α-myristoyl-PYY(22-36) (SEQ. ID. NO. 18) reduced the basal SCC by - 5.2±0.6μA/0.6cm2 (n = 7) . Subsequent addition of PYY (100 nM) further reduced the SCC by
-10.2±0.7μA/0.6cm2 (n = 7) and this was not significantly different from control responses to PYY(22-36) (SEQ. ID. NO. 10) could antagonize PYY responses, three tissues were treated with the analog (lμM) and PYY concentration- response curves were constructed and compared with controls. The fragment reduced the basal current by - 0.4±0.3 μA/0.6cm2 and the resultant PYY EC50 value
(4.411.2 nM, n = 3) did not differ significantly from that of the nontreated controls (2.611.1 nM, n = 3).
These results show that modification of the active site of PYY (SEQ. ID. NO. 1), PYY(22-36) (SEQ. ID. NO.
10) , can lead to a substantial increase in both the binding and antisecretory potencies of this fragment.
The key analogs in this series exhibited the following order of potency: PYY (SEQ. ID. NO. 1) > N-α-Ac-
[Phe27]PYY(22-36) (SEQ. ID. NO. 3) > N-α-Ac-PYY(22-36) (SEQ. ID. NO. 14) > PYY(22-36) (SEQ. ID. NO. 10). Furthermore, our investigations revealed that the hydroxyl groups of Ser23 and Thr32 as well as the imidazole group of His26 are important for interaction with intestinal PYY- preferring receptors. Although there was, in general, a good correlation between the binding and antisecretory potencies of the analogs, there were also notable
exceptions. N-α-myristoyl-PYY (22-36) (SEQ. ID. NO. 18) and N-α- naphthaleneacetyl-PYY (22-36) (SEQ. ID. NO. 19) analogs inhibited 125I-PYY binding with moderate potency, but exhibited poor antisecretory responses. This observation suggested that these analogs may be antagonists.
However, prior pretreatment of jejunal membranes with these analogs failed to significantly alter the
antisecretory responses to PYY and the reason for the discrepancy remains unclear at present.
Table 2 and Fig. 4 present the IC50 values for additonal PYY (22-36) (SEQ. ID. NO. 10) and PYY (25-36) analogs. Based on the results presented in Table 2 the analogs in this series exhibited the following order of potency:
N-α-Ac-[Tic27]PYY(22-36) (SEQ. ID. NO. 25) < N-α-Ac- [Bip27]PYY (22-36) (SEQ. ID. NO. 22) < N-α-Ac- [Nal27]PYY (22-36) (SEQ. ID. NO. 23) < N-α-Ac- [Bth27]PYY(22-36) (SEQ. ID. NO. 21) < N-α-Ac- [Phe27]PYY(22-36) (SEQ. ID. NO. 3) < N-α-Ac-[Phe27]PYY(25- 36) (SEQ. ID. NO. 26) < N-α-Ac-[Trp27]PYY(22-36) (SEQ. ID. NO. 5) < N-α-Ac-[Thi27]PYY(22-36) (SEQ. ID. NO. 6) < N-α- AC-PYY (22-36) (SEQ. ID. NO. 14) < PYY (SEQ. ID. NO. 1).
TABLE 2 Comparison of Receptor Binding Data for PYY and PYY analo s
Figure imgf000026_0001
NPY/PYY receptors characterized to date have been broadly classified into Y-1, Y-2 and Y-3 subtypes
(Balsubramaniam et al. J. Biol . Chem. 265:14724, 1990; Michel, Trends Pharmacol . Sci . 12:389, 1991). Both Y-1 and Y-2 receptors exhibit a preference for PYY over NPY, and more significantly C-terminal fragments of NPY and PYY are effective only at the Y-2 subtype. Y-3
receptors, on the other hand, exhibit a greater affinity for NPY than PYY. Since rat jejunal mucosa antisecretory responses show an order of agonist potency PYY (SEQ. ID. NO. 1)> NPY (SEQ. ID. NO. 24) > PYY(13-36) (SEQ. ID. NO. 32) > NPY(13-36) (SEQ. ID. NO. 33) these epithelial receptors are Y-2 like, and are completely insensitive to the Y-1 selective agonist [Pro34]NPY (Cox et al. Peptides, supra) . The results further describe N-α-Ac-PYY (22-36) (SEQ. ID. NO. 14) and N-α-Ac-[Phe27] PYY (22-36) (SEQ. ID. NO. 3) to be more potent than PYY (22-36) (SEQ. ID. NO. 10) and the corresponding C-terminal fragments of NPY of varying lengths (Cox et al. Br. J. Pharmacol , supra) .
The higher affinity for PYY (SEQ. ID. NO. 1) and its C- terminal fragments compared with NPY (SEQ. ID. NO. 24) and its respective fragments is in agreement with the order of potency obtained from receptor binding studies with rat intestinal epithelial membranes (Laburthe et al. supra ; Laburthe, supra ; Voisin et al. Ann . N. Y. Acad.
Sci . supra ; Voisin et al. Am . J. Physiol . )
In addition, analogs listed in Table 3 were synthesized as described above and tested for binding activity. The results shown in Table 3 demonstrate that N-α-Ac- [Tyr22, Phe27]PYY(22-36) (SEQ. ID. NO. 7) is similar in its competitive binding as PYY (SEQ. ID. NO. 1), indicating that the introduction of an aromatic amino acid, e.g., Tyr, at position 22 is an effective PYY analog.
TABLE 3
Figure imgf000028_0001
USE
In the practice of the method of the present invention, an effective amount of an any one or
combination of the analogs of the invention, e.g., N-α- Ac-[Phe27]PYY(22-36) (SEQ. ID. NO. 3), N-α-Ac- [Trp27]PYY(22-36) (SEQ. ID. NO. 24), N-α-Ac-[Phe27]PYY(25- 36) (SEQ. ID. NO. 3), N-α-Ac-[Thi27]PYY(22-36) (SEQ. ID. NO. 6) or derivative thereof, is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another compound or
compounds of the present invention. These compounds or compositions can thus be administered orally (e.g., buccal cavity), sublingually, parenterally (e.g., intramuscularly, intravenously, or subcutaneously), rectally ( e.g., by. suppositories or washings),
transdermally (e.g., skin electroporation) or by
inhalation (e.g., by aerosol), and in the form or either solid, liquid or gaseous dosage, including tablets and suspensions. The administration can be conducted in a single unit dosage form with continuous therapy or in a single dose therapy ad libitum. Thus, the method of the present invention is practiced when relief of symptoms is specifically
required or perhaps imminent. Alternatively, the method of the present invention is effectively practiced as continuous or prophylactic treatment.
Useful pharmaceutical carriers for the preparation of the compositions hereof, can be solids, liquids or gases; thus, the compositions can take the form of tablets, pills, capsules, suppositories, powders,
enterically coated or other protected formulations (e.g. binding on ion-exchange resins or packaging in lipid- protein vesicles), sustained release formulations, solutions, suspensions, elixirs, aerosols, and the like. The carrier can be selected from the various oils
including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic with the blood) for
injectable solutions. For example, formulation for intravenous administration comprise sterile aqueous solutions of the active ingredient(s) which are prepared by dissolving solid active ingredient(s) in water to produce an aqueous solution, and rendering the solution sterile. Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, talc, gelatin, malt, rice, flour, chalk, silica, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. The compositions may be subjected to conventional pharmaceutical additives such as
preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers and the like. Suitable pharmaceutical carriers and their formulation are described in Remington 's Pharmaceutical Sciences by E.W. Martin. Such compositions will, in any event, contain an effective amount of the active compound together with a suitable carrier so as to prepare the proper dosage form for proper administration to the recipient.
The dose of the compound of the present invention for treating the above-mentioned disorders varies
depending upon the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian. Such amount of the active compound as determined by the attending physician or veterinarian is referred to herein as a "therapeutically effective amount". Thus, a typical administration is oral administration or parenteral administration. The daily dose in the case of oral administration is typically in the range of 0.1 to 100 mg/kg body weight, and the daily dose in the case of parenteral administration is typically in the range of 0.001 to 50 mg/kg body weight.
To be effective for the prevention or treatment of gastroenterological disorders, especially infectious (e.g. viral or bacterial) or inflammatory diarrhea, or diarrhea resulting from surgery, it is important that the therapeutic agents be relatively non-toxic, non-antigenic and non-irritating at the levels in actual use.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

Claims

Claims :
1. A compound having the formula:
R1 R3
R2-X-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-Y
Figure imgf000031_0001
-R4 wherein
X is a chain of 0-5 amino acids, inclusive, the N-terminal one of which is bonded to R1 and R2;
Y is a chain of 0-4 amino acids, inclusive, the C-terminal one of which is bonded to R3 and R4;
R1 is H, C1-C12 alkyl, C6-C18 aryl, C1-C12 acyl,
C7-C18 aralkyl, or C7-C18 alkaryl;
R2 is H, C1-C12 alkyl, C6-C18 aryl, C1-C12 acyl,
C7-C18 aralkyl, or C7-C18 alkaryl;
A22 is an aromatic amino acid, Ala,
Aib, Anb, N-Me-Ala, or is deleted;
A23 is Ser, Thr, Ala, Aib, N-Me-Ser, N-Me-Thr, N-
Me-Ala, D-Trp, or is deleted;
A24 is Leu, Gly, lle, Val, Trp, Aib, Anb,
N-Me-Leu, or is deleted;
A25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight hain C1-C10 alkyl group, or an aryl group), Orn or is deleted;
A25 is Ala, His, Thr, 3-Me-His, 1-Me-His,
β-pyrozolylalanine, N-Me-His, Arg, Lys, homo-
Arg, diethyl-homo-Arg, Lys-e-NH-R (where R is H, a branched chain or straight chain C1-C10 alkyl group, or an aryl group), Orn, or is deleted;
A27 is an aromatic amino acid other than Tyr;
A28 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu; A29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn; A30 is Leu, lie, Val, Trp, Aib, Anb, or N-Me-Leu;
A31 is Val, Ile, Trp, Aib, Anb, or N-Me-Val;
A32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp;
R3 is H, C1-C12 alkyl, C6-C18 aryl, C1-C12 acyl, C7-C18 aralkyl, or C7-C18 alkaryl; and
R4 is H, C1-C12 alkyl, C6-C18 aryl, C1-C12 acyl, C7-C18 aralkyl, C7-C18 alkaryl, or a
pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein A27 is Phe, Nal, Bip, Pep, Tic, Trp, Trp, Bth, Thi, or Dip.
3. The compound of claim 1, where X is A17-A18- A19-A20-A21 Wherein
A17 is Cys, Leu, Ile, Val, Aib, Anb, or N-Me-Leu; A18 is Cys, Ser, Thr, N-Me-Ser, or N-Me-Thr;
A19 is Cys, Arg, Lys, homo-Arg, diethyl-homo-Arg,
Lys-e-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), or Orn;
A20 is an aromatic amino acid or Cys; and A21 is an aromatic amino acid, Cys, or a
pharmaceutically acceptable salt thereof.
4. The compound of claim 1, where Y is A33-
A34-A35-A36 wherein
A33 is Cys, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), or Orn;
A34 is Cys, Gln, Asn, Ala, Gly, N-Me-Gln, Aib, or
Anb;
A35 is Cys, Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys-ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), or Orn; and
A36 is an aromatic amino acid, Cys, or a
pharmaceutically acceptable salt thereof.
5. The compound of claim 4, wherein said compound has the formula:
N-α-Ac-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg- Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 3), or a pharmaceutically acceptable salt thereof.
6. The compound of claim 4, wherein said compound has the formula:
H-Ala-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln- Arg-Tyr-NH2 (SEQ. ID. NO. 4), or a pharmaceutically acceptable salt thereof.
7. The compound of claim 4, wherein said compound has the formula:
N-α-Ac-Ala-Ser-Leu-Arg-His-Trp-Leu-Asn-Leu-Val-Thr-Arg- Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 5), or a pharmaceutically acceptable salt thereof.
8. The compound of claim 4, wherein said compound has the formula:
N-α-Ac-Ala-Ser-Leu-Arg-His-Thi-Leu-Asn-Leu-Val-Thr-Arg- Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 6), or a pharmaceutically acceptable salt thereof.
9. The compound of claim 4, wherein said compound has the formula:
N-α-Ac-Tyr-Ser-Leu-Arg-His-Phe-Leu-Asn-Leu-Val- Thr-Arg-Gln-Arg-Tyr-NH2 (SEQ. ID. NO. 7), or a
pharmaceutically acceptable salt thereof.
10. A compound having the formula:
R1 R3
Figure imgf000035_0001
R2-A25-A26-A27-A28-A29-A30-A31-A32-Y-R4 wherein
the N-terminal amino acid is bonded to R1 and R2; Y is a chain of 0-4 amino acids, inclusive the C-terminal one of which is bonded to R3 and R4;
R-L is H, C2-C12 alkyl, C6-C18 aryl, C1-C12 acyl, C7-C18 aralkyl, or C7-C18 alkaryl;
R2 is H, C1-C12 alkyl, C6-C18 aryl, C1-C12 acyl,
C7-C18 aralkyl, or C7-C18 alkaryl;
A25 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group),
Orn or is deleted;
A26 is Ala, His, Thr, 3-Me-His, 1-Me-His, β-pyrozolylalanine, N-Me-His, Arg, Lys, homo- Arg, diethyl-homo-Arg, Lys-e-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or an aryl group), Orn or is deleted; A27 is an aromatic amino acid;
A28 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu; A29 is Asn, Ala, Gin, Gly, Trp, or N-Me-Asn; A30 is Leu, Ile, Val, Trp, Aib, Anb, or N-Me-Leu; A31 is Val, Ile, Trp, Aib, Anb, or N-Me-Val; A32 is Thr, Ser, N-Me-Ser, N-Me-Thr, or D-Trp;
R3 is H, C1-C10 alkyl, C6-C18 aryl, C1-C12
acyl, C7-C18 aralkyl, or C7-C18 alkaryl; and R4 is H, C1-C12 alkyl, C6-C18 aryl, C1-C12 acyl,
C7-C18 aralkyl or C7-C18 alkaryl, or a
pharmaceutically acceptable salt thereof.
11. The compound of claim 10, wherein A27 is Phe, Nal, Bip, Pep, Tic, Trp, Bth, Thi, or Dip.
12. The compound of claim 10, wherein Y is A33-. A34-A35-A36 wherein
A33 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), Cys, or Orn;
A34 is Cys, Gln, Asn, Ala, Gly, N-Me-Gln, Alb, or Anb;
A35 is Arg, Lys, homo-Arg, diethyl-homo-Arg, Lys- ε-NH-R (where R is H, a branched or straight chain C1-C10 alkyl group, or C6-C18 aryl group), Cys, or Orn; and
A36 is an aromatic amino acid, Cys, or a
pharmaceutically acceptable salt thereof.
13. The compound of claim 12, wherein said compound has the formula:
N-α-Ac-Arg-His-Phe-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr- NH2 (SEQ. ID. NO. 26), or a pharmaceutically acceptable salt thereof.
14. A therapeutic composition capable of decreasing excess intestinal water and electrolyte secretion, said composition comprising a therapeutically effective amount of the compound of claim 1 and claim 10, together with a pharmaceutically acceptable carrier substance.
15. A method of decreasing excess intestinal water and electrolyte secretion in a mammal, said method comprising administering to said mammal a therapeutically effective amount of the composition of claim 14.
16. A method of regulating cell proliferation in a mammal, said method comprising administering to said mammal a therapeutically effective amount of the
composition of claim 14.
17. A method of augmenting nutrient transport in a mammal, said method comprising administering to said mammal a therapeutically effective amount of the
composition of claim 14.
18. A method or regulating lipolysis in a mammal, said method comprising adminsitering to said mammal a therapeutically effective amount of the composition of claim 14.
19. A method of regulating blood flow in a mammal, said method comprising adminsitering to said mammal a therapeutically effective amount of the
composition of claim 14.
20. A dimeric compound comprising either two peptides of claim 10, or one peptide of claim l or one peptide of claim 10, wherein said dimer is formed by either an amide bo, or a disulfide bridge between said two peptides.
PCT/US1994/003380 1993-03-29 1994-03-29 Analogs of peptide yy and uses thereof WO1994022467A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU66214/94A AU685803B2 (en) 1993-03-29 1994-03-29 Analogs of peptide YY and uses thereof
EP94913965A EP0692971A4 (en) 1993-03-29 1994-03-29 Analogs of peptide yy and uses thereof
JP6522278A JPH08510205A (en) 1993-03-29 1994-03-29 YY peptide analogs and their uses
KR1019950704035A KR960701653A (en) 1993-03-29 1994-03-29 Analogs of Peptide YY and Uses thereof
SK1218-95A SK121895A3 (en) 1993-03-29 1994-03-29 Analogues of peptide yy and uses thereof
FI954559A FI954559A (en) 1993-03-29 1995-09-26 YY peptide analogues and their uses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3853493A 1993-03-29 1993-03-29
US08/038,534 1993-03-29
US10932693A 1993-08-19 1993-08-19
US08/109,326 1993-08-19

Publications (1)

Publication Number Publication Date
WO1994022467A1 true WO1994022467A1 (en) 1994-10-13

Family

ID=26715298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/003380 WO1994022467A1 (en) 1993-03-29 1994-03-29 Analogs of peptide yy and uses thereof

Country Status (14)

Country Link
US (1) US5604203A (en)
EP (1) EP0692971A4 (en)
JP (1) JPH08510205A (en)
KR (1) KR960701653A (en)
CN (1) CN1124927A (en)
AU (1) AU685803B2 (en)
CA (1) CA2157766A1 (en)
FI (1) FI954559A (en)
HU (1) HUT73494A (en)
NZ (1) NZ265452A (en)
PL (1) PL310897A1 (en)
SG (1) SG52542A1 (en)
SK (1) SK121895A3 (en)
WO (1) WO1994022467A1 (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735983A1 (en) * 1995-06-29 1997-01-03 Centre Nat Rech Scient Medical use of peptide(s) with polycationic amphiphilic alpha-helical sequence
WO1997046579A1 (en) * 1996-06-05 1997-12-11 Peptech Limited Neuropeptide y agonists
US5958709A (en) * 1993-12-28 1999-09-28 Synaptic Pharmaceutical Corporation Processes for identifying compounds that bind to the human Y4 receptor
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5989834A (en) * 1994-02-03 1999-11-23 Synaptic Pharmaceutical Corporation Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding
WO2001058409A2 (en) * 2000-02-08 2001-08-16 North Carolina State University Method of reducing aluminum levels in the central nervous system
WO2001076631A2 (en) * 2000-04-10 2001-10-18 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6316203B1 (en) 1994-12-02 2001-11-13 Synaptic Pharmaceutical Corporation Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US6696409B1 (en) 1996-06-05 2004-02-24 Prince Of Wales Medical Research Institute Limited (Powmr Ltd.) Neuropeptide Y agonists
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
AU772915B2 (en) * 1996-06-05 2004-05-13 Prince Of Wales Medical Research Institute Limited Neuropeptide Y agonists
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
WO2006066024A2 (en) 2004-12-13 2006-06-22 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2006077035A1 (en) * 2005-01-18 2006-07-27 F.Hoffmann-La Roche Ag Peptides with neuropeptide-2 receptor (y2r) agonist activity
US7157426B2 (en) 2002-12-17 2007-01-02 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
AU2007200008B2 (en) * 2000-04-10 2008-09-11 Cedars-Sinai Medical Center Methods for Manipulating Upper Gastrointestinal Transit, Blood Flow, and Satiety, and for Treating Visceral Hyperalgesia
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
EP2330125A3 (en) * 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8697647B2 (en) 2004-02-11 2014-04-15 Odile Esther Levy Hybrid polypeptides with selectable properties
US9358276B2 (en) 1999-08-11 2016-06-07 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912227A (en) * 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5916869A (en) * 1997-06-13 1999-06-29 North Carolina State University Method of treating birds in ovo
JP4394279B2 (en) * 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ Pharmacologically active peptide conjugates with reduced propensity to enzymatic hydrolysis
US6046167A (en) * 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
ATE482717T1 (en) 1999-02-10 2010-10-15 Curis Inc PEPTIDE YY (PYY) FOR THE TREATMENT OF GLUCOSE METABOLIC DISEASES
US7745216B2 (en) * 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
JP2004515533A (en) 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド Peptide YY and peptide YY agonist for treating metabolic disorders
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
DE60335639D1 (en) * 2002-06-14 2011-02-17 Amylin Pharmaceuticals Inc PREVENTION AND / OR TREATMENT OF COLITIS ULCEROSA WITH PYY OR PYYE3-36Ü
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
JP5638177B2 (en) * 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc Pancreatic polypeptide family motif and polypeptide containing the motif
CA2555877C (en) * 2004-02-11 2015-11-24 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
MXPA06010347A (en) * 2004-03-17 2007-06-19 7Tm Pharma As Y2 selective receptor agonists for therapeutic interventions.
US20080261871A1 (en) * 2004-03-17 2008-10-23 7Tm Pharma A/S Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
CN1953763A (en) * 2004-03-17 2007-04-25 7Tm制药联合股份有限公司 Y4 selective receptor agonists for therapeutic interventions
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
PA8660701A1 (en) * 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
AU2005337116A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
CA2623094A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
RU2008116844A (en) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Acylated Spiropiperidine Derivatives as Modulators of the Melanocortin-4 Receptor
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
CA2758415C (en) 2008-04-14 2019-06-04 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
PT3178835T (en) 2009-02-03 2019-06-19 Amunix Pharmaceuticals Inc Extended recombinant polypeptides and compositions comprising same
JP5767582B2 (en) 2009-07-02 2015-08-19 武田薬品工業株式会社 Peptides and their uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RS60321B1 (en) 2010-12-16 2020-07-31 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
PE20142451A1 (en) 2012-02-27 2015-02-04 Amunix Operating Inc COMPOSITIONS OF CONJUGATES OF XTEN AND METHODS TO MAKE THEM
MX353067B (en) 2012-03-22 2017-12-19 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof.
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
AU2016275735B2 (en) * 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
CN109890205A (en) 2016-08-28 2019-06-14 以色列农业和农村发展部农业研究组织(范卡尼中心) The method for controlling the fungal infection in plant
CN111683676A (en) 2018-02-02 2020-09-18 诺和诺德股份有限公司 Solid compositions comprising a GLP-1 agonist, a salt of N- (8- (2-hydroxybenzoyl) amino) octanoic acid, and a lubricant
EP4058466A1 (en) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS646294A (en) * 1987-02-09 1989-01-10 Ajinomoto Kk Novel peptide derivative
US5026685A (en) * 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS646294A (en) * 1987-02-09 1989-01-10 Ajinomoto Kk Novel peptide derivative
US5026685A (en) * 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chem. Pharm. Bull., Volume 36, No. 7, issued 1988, T. ISHIGURO et al., "Synthesis of Peptide Fragments of Neuropeptide Y: Potent Inhibitors of Calmodulin-Stimulated Phosphodiesterase", pages 2720-2723, especially Table II. *
J. Med. Chem., Volume 35, issued 1992, FEINSTEIN et al., "Structural Requirements for Neuropeptide Y18-36-Evoked Hypotension: A Systematic Study", pages 2836-2843, especially Compound Number 24 in Table I. *
Peptides, Volume 14, issued 1993, A. BALASUBRAMANIAM et al., "Structure-Activity Studies of Peptide YY(22-36): N-Alpha-Ac-(Phe27)PYY(22-36), a Potent Antisecretory Peptide in Rat Jejunum", pages 1011-1016, especially Table I. *
See also references of EP0692971A4 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958709A (en) * 1993-12-28 1999-09-28 Synaptic Pharmaceutical Corporation Processes for identifying compounds that bind to the human Y4 receptor
US5976814A (en) * 1993-12-28 1999-11-02 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US6913892B1 (en) 1993-12-28 2005-07-05 H. Lundbeck A/S Method of obtaining compositions comprising Y4 specific compounds
US5989834A (en) * 1994-02-03 1999-11-23 Synaptic Pharmaceutical Corporation Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding
US6420532B1 (en) 1994-02-03 2002-07-16 Synaptic Pharmaceutical Corporation Method of obtaining compositions comprising Y2 specific compounds
US6818445B2 (en) 1994-12-02 2004-11-16 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US6316203B1 (en) 1994-12-02 2001-11-13 Synaptic Pharmaceutical Corporation Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US6645774B1 (en) 1994-12-02 2003-11-11 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior using compounds with afinity for the human hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
FR2735983A1 (en) * 1995-06-29 1997-01-03 Centre Nat Rech Scient Medical use of peptide(s) with polycationic amphiphilic alpha-helical sequence
US6440690B1 (en) 1995-06-29 2002-08-27 Amram Mor Peptides for the activation of the immune system in humans and animals
AU772915B2 (en) * 1996-06-05 2004-05-13 Prince Of Wales Medical Research Institute Limited Neuropeptide Y agonists
WO1997046579A1 (en) * 1996-06-05 1997-12-11 Peptech Limited Neuropeptide y agonists
US6696409B1 (en) 1996-06-05 2004-02-24 Prince Of Wales Medical Research Institute Limited (Powmr Ltd.) Neuropeptide Y agonists
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US7906482B2 (en) 1999-05-17 2011-03-15 Advanced Diagnostics And Discovery Anti-obesity agents
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US9358276B2 (en) 1999-08-11 2016-06-07 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO2001058409A3 (en) * 2000-02-08 2002-02-21 Univ North Carolina State Method of reducing aluminum levels in the central nervous system
US6734166B1 (en) * 2000-02-08 2004-05-11 North Carolina State University Method of reducing aluminum levels in the central nervous system
WO2001058409A2 (en) * 2000-02-08 2001-08-16 North Carolina State University Method of reducing aluminum levels in the central nervous system
WO2001076631A2 (en) * 2000-04-10 2001-10-18 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
EP1875909A2 (en) * 2000-04-10 2008-01-09 Cedars-Sinai Medical Center Use of antagonists of PYY receptors for treating irritable bowel syndrome
WO2001076631A3 (en) * 2000-04-10 2002-03-21 Cedars Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
AU2001251396B2 (en) * 2000-04-10 2006-10-26 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
AU2007200008B2 (en) * 2000-04-10 2008-09-11 Cedars-Sinai Medical Center Methods for Manipulating Upper Gastrointestinal Transit, Blood Flow, and Satiety, and for Treating Visceral Hyperalgesia
EP1905446A1 (en) * 2000-04-10 2008-04-02 Cedars-Sinai Medical Center Use of PYY analogs and antagonists of PPY receptors for manipulating satiety
EP1875909A3 (en) * 2000-04-10 2008-02-27 Cedars-Sinai Medical Center Use of antagonists of PYY receptors for treating irritable bowel syndrome
EP1891963A1 (en) * 2000-04-10 2008-02-27 Cedars-Sinai Medical Center Use of antagonists of PPY receptors for treating visceral pain or visceral hypersensitivity
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186691B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7157426B2 (en) 2002-12-17 2007-01-02 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
US7811989B2 (en) 2003-01-17 2010-10-12 Ipsen Pharma S.A.S. Peptide YY analogs
EP2277527A2 (en) 2003-01-17 2011-01-26 Ipsen Pharma Peptide YY analogs
US9453063B2 (en) 2004-02-11 2016-09-27 Amylin Pharmaceuticals, Llc. Hybrid polypeptides with selectable properties
US8697647B2 (en) 2004-02-11 2014-04-15 Odile Esther Levy Hybrid polypeptides with selectable properties
WO2006066024A2 (en) 2004-12-13 2006-06-22 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP2360180A2 (en) 2004-12-13 2011-08-24 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP3000826A1 (en) 2004-12-13 2016-03-30 Amylin Pharmaceuticals, LLC Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
WO2006077035A1 (en) * 2005-01-18 2006-07-27 F.Hoffmann-La Roche Ag Peptides with neuropeptide-2 receptor (y2r) agonist activity
KR100905380B1 (en) 2005-01-18 2009-06-30 에프. 호프만-라 로슈 아게 Peptides with neuropeptide-2 receptory2r agonist activity
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
EP2330125A3 (en) * 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists

Also Published As

Publication number Publication date
PL310897A1 (en) 1996-01-08
AU6621494A (en) 1994-10-24
FI954559A0 (en) 1995-09-26
EP0692971A4 (en) 1997-11-12
AU685803B2 (en) 1998-01-29
FI954559A (en) 1995-09-26
CN1124927A (en) 1996-06-19
EP0692971A1 (en) 1996-01-24
CA2157766A1 (en) 1994-10-13
NZ265452A (en) 1997-09-22
HU9502833D0 (en) 1995-11-28
JPH08510205A (en) 1996-10-29
HUT73494A (en) 1996-08-28
SG52542A1 (en) 1998-09-28
KR960701653A (en) 1996-03-28
US5604203A (en) 1997-02-18
SK121895A3 (en) 1996-10-02

Similar Documents

Publication Publication Date Title
US5604203A (en) Analogs of peptide YY and uses thereof
US6046167A (en) Peptide YY analogs
US6242563B1 (en) Peptide analogues
WO1998020885A1 (en) Analogs of peptide yy and uses thereof
EP0707490A1 (en) Neuropeptide y antagonists and agonists
CA2428552A1 (en) Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US20070287665A1 (en) Urotensin-II agonists and antagonists
WO1999040928A1 (en) Novel mixed amylin activity compounds
EP0541654A1 (en) Bombesin antagonists
AU2002232903A1 (en) Urotensin-II agonists and antagonists
JP2003073301A (en) Neurotoxin toxicity-reducing agent
EP1878743A2 (en) Urotensin-II agonists and antagonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94192277.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2157766

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 265452

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 954559

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1994913965

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 121895

Country of ref document: SK

WWP Wipo information: published in national office

Ref document number: 1994913965

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994913965

Country of ref document: EP